In Switzerland, about 41'700 people are newly diagnosed with cancer each year, about 16'900 die of it, and about 64% still live 5 years after diagnosis.
In 2018, more than 18 million people worldwide were diagnosed with cancer. More than 9 million people died of it.
All cells in our body have certain jobs to do. Normal cells divide in an orderly way. They die when they are worn out or damaged, and new cells take their place. In cancer, cells divide uncontrollably and crowd out the normal cells. This causes discomfort in the part of the body where the cancer started. Cancer cells can also spread to other parts of the body. Most cancers form lumps, which are also called tumors.
Some cancers grow and spread fast. Others grow more slowly. They also respond to treatment in different ways. For example, some types of cancer can be treated well with surgery, while others respond better to drugs like chemotherapy, immunotherapy or a combination of different therapies. Often more than one treatment is used.
Biomarkers are certain biological characteristics that can be measured in blood or tissue samples. They help to better understand a cancer disease and can provide information for the choice of a treatment option. There are several biomarkers, MSI-H/dMMR is one of them.
Tumors with high microsatellite instability often respond better to certain therapies. An MSI biomarker test can help to identify patients who may respond to such therapy.
Every cancer is different. To help develop a treatment plan that is right for a patient, the doctor may order laboratory tests. These tests are used to evaluate the tumor for various biomarkers, including MSI-H/dMMR.
Biomarker research has made significant progress to date, providing cancer patients with new treatment options.